Sunrise Pharmaceutical has recently achieved a significant milestone, successfully navigating the EU GMP (Good Manufacturing Practice) re-inspection and securing a prestigious GOOD grade, entitling them to an extended inspection interval of up to 33 months. This accomplishment underscores Sunrise Pharmaceutical's adherence to international standards in veterinary drug production quality and signifies the global recognition of its robust quality management system and manufacturing prowess by esteemed certification bodies.

In 2013, Sunrise Pharmaceutical's veterinary drug production line initially aced the EU GMP on-site inspection. From May 30th to 31st, 2024, the company once again demonstrated its commitment to excellence as inspectors from the Veterinary Medicines Directorate in the UK conducted a meticulous, exhaustive, and in-depth review of its quality system, leaving them with a favorable assessment.

As a pivotal standard in the global pharmaceutical landscape, GMP demands that enterprises embed a meticulous quality control system throughout the entire drug production process, guaranteeing safe, efficient, and stable medications. Its certification/inspection process carries immense weight globally, serving as a testament to a company's commitment to excellence. The recent inspection, meticulously examining finished product manufacturing workshops, laboratories, warehouses, and the intricate web of quality management system documents and records, underscores the paramount significance of pharmaceutical production and quality assurance.

Amid the relentless pace of innovation and rapid advancements sweeping through the global pharmaceutical industry, Sunrise Pharmaceutical steadfastly maintains its dedication to driving the internationalization of its facilities. The company commits to delivering safe, effective, and premium-quality veterinary drugs, safeguarding the health and well-being of animals worldwide.